Phase I study results support further evaluation of yellow fever monoclonal antibody TY-014 Aug. 13, 2020
FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy Aug. 13, 2020
VBL announces second successful pre-planned interim analysis of the phase III OVAL study Aug. 13, 2020
RSS